阿维鲁单抗联合间歇性阿昔替尼治疗初治转移性肾细胞癌:TIDE-A 2期研究
TIDE-A 为单臂2期试验,入组79例初治转移性肾细胞癌患者,接受阿昔替尼联合阿维鲁单抗治疗,36周后达肿瘤缓解者中断阿昔替尼、继续阿维鲁单抗维持。主要终点为中断阿昔替尼后8周无进展率,29例(38%)中断阿昔替尼者中72%达到主要终点;总体中位无进展生存24个月,中位总生存未达到,客观缓解率76%。
要点
- 79例初治转移性肾细胞癌患者入组,75例可评估疗效。
- 29例(38%)按设计中断阿昔替尼,其中72%在中断后8周无进展。
- 总体客观缓解率76%(完全缓解12%、部分缓解64%),19%疾病稳定。
核心结论
- TIDE-A研究表明,对一线阿昔替尼联合阿维鲁单抗有缓解证据的选择性转移性肾细胞癌患者,中断VEGFR-TKI并继续ICI维持治疗是可行的。
- 阿昔替尼中断联合阿维鲁单抗维持使副作用减少,应作为延迟肿瘤进展的新策略进一步研究。
研究设计与样本
- 单臂2期试验,入组初治转移性肾细胞癌患者,要求既往肾切除术、无有症状/大块病灶且无肝转移。
- 患者接受阿昔替尼联合阿维鲁单抗治疗,36周后达肿瘤缓解者中断阿昔替尼并继续阿维鲁单抗维持直至疾病进展。
- 主要终点为中断阿昔替尼后8周无进展患者比例,次要终点为总体人群中位无进展生存期、中位总生存期及安全性。
主要发现
- 79例患者入组,75例可评估疗效。
- 29例(38%)按研究设计中断阿昔替尼,其中72%在中断后8周无进展,达到主要终点。
- 总体人群中位无进展生存期为24个月,中位总生存期未达到。
- 客观缓解率为76%(完全缓解12%、部分缓解64%),19%患者疾病稳定。
- 中断阿昔替尼患者中,任何级别不良事件发生率为59%,3或4级不良事件发生率为3%。
局限性
- 本研究缺乏对照臂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Combinations of VEGFR-TKIs plus ICI against PD1/PD-L1 are the standard first-line therapy for patients with mRCC, irrespective of the prognostic class. This study aims to investigate the feasibility and safety of withdrawing the VEGFR-TKI but continuing the anti- PD1/PD-L1 in patients who achieve response to their combination. METHODS: This was a single-arm phase 2 trial in patients with treatment naïve mRCC with prior nephrectomy, without symptomatic/bulky disease and no liver metastases. Enrolled patients received axitinib+avelumab, after 36 weeks of therapy those who achieved tumor response interrupted axitinib and continued avelumab maintenance until disease progression. The primary endpoint was the rate of patients without progression eight weeks after the axitinib interruption. Secondary endpoints were the median value for progression free (mPFS) and overall survival (mOS) and the safety in the overall population. KEY FINDINGS AND LIMITATIONS: 79 patients were enrolled and 75 evaluated for efficacy. A total of 29 (38%) patients had axitinib withdrawn, as per the study design, with 72% of them having no progression after eight weeks and thus achieving the primary endpoint. The mPFS of the overall population was 24 months while the mOS was not reached. The ORR was 76% (12% CR, 64% PR), with 19% of patients having stable disease. In the patients who discontinued axitinib, the incidence of AEs of any grade was 59% and 3% for grade 3 or 4. This study was limited by the lack of the comparative arm. CONCLUSIONS AND CLINICAL IMPLICATIONS: The TIDE-A study demonstrates that the withdrawal of VEGFR-TKI with ICI maintenance is feasible for selected mRCC patients with evidence of response to the VEGFR-TKI+ICI combination employed in first-line therapy. Axitinib interruption with avelumab maintenance led to decreased side effects and should be further investigated as a new strategy to delay tumor progression.
引用
- Iacovelli R, Ciccarese C, Buti S, et al. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study. Eur Urol. 2024. PMID: 38521617. doi:10.1016/j.eururo.2024.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。